remain posit follow call pharmedium appear back track
compli w/ regul despit exclus memphi facil management abl
maintain adj ep guidanc least low end rang due out-performance
core distribut busi sign improv lash also posit
pharmedium work remedi work fda fulli
compli regul compound qualiti prioriti remain commit
memphi facil closur result y/i volum reduct
affect pharma segment gross profit neg rev management note
pharmedium due lost revenue fewer shipment less gross profit due
remedi cost think give investor comfort know remain
commit reopen memphi facil time manner
memphi facil expect oper expect memphi facil
fulli oper brought on-board phase manner
longer timelin expect believ earlier investor
expect mani like struggl determin timelin follow
file april file fulli exclud memphi facil model
consensu like cautiou least model includ
contribut memphi facil
pharma continu outperform strength core distribut evidenc
grow gener volum despit continu deflat well strength grew
y/i perform stronger street expect believ
could continu remaind core posit includ
hd smith integr track line management expect solid revenue growth
independ segment sooner expect onboard store
lash show sign turn around despit solid perform world courier
mwi lash experienc setback due slower expect fusion implement
howev management comment suggest thing improv lash recent secur
sever new win onboard fusion largest manufactur program date
good result high custom satisfact feedback
updat outlook
updat guidanc due pharmedium management assum contribut
memphi facil remaind exclud remedi
cost incur due one-tim natur expect adj opex grow
result flat y/i adj op incom growth
reduct relat pharma ie pharmedium remaind due lash
despit downward revis pharma segment management abl
maintain adj ep guidanc rang least low end due lower tax
pleas see page report import disclosur
posit think on-going transit custom new
price model break specialti result margin expans drive growth
profit addit sourc benefit wbad help drive margin
profit medium-term volum esrx onboard onboard
store acquir also serv near-term tailwind
 statu remedi
 top-lin growth driven specialti
includ alliancerx acquisit hd
smith store acquir
 gross margin
 ebit margin
 top-lin growth low-teen due
greater expect growth specialti
 top-lin growth mid-singl digit
due lower brand inflat
 gm due better
expect purchas effici
 sg better expect due
 share come lower due greater
expect share repo
 margin closer due higher
expect gener deflat lower
 sg come wors expect
 share come higher due lower
one three largest pharmaceut distribut compani
 servic pharmaceut manufactur health care provid
pharmaceut suppli channel primarili provid drug distribut relat servic
distribut comprehens offer brand name gener pharmaceut over-the-
counter health care product home health care suppli equip wide varieti
health care provid locat throughout includ acut care hospit
health system independ chain retail pharmaci mail-ord facil physician
clinic altern site facil skill nurs assist live center
onboard management note complet transit store earlier
origin expect expect full quarter impact
guidanc adj tax rate expect slightli prior guidanc
due better contribut account share-bas comp
benefit maintain adj ep guidanc although management indic
low end rang compar consensu
updat estim price target
lower adj ep estim rais adj ep
estim ramp contribut pharmedium
memphi facil throughout start rais price target
base revis dcf analysi impli share trade
adj ep estim current valuat
million except per-shar data
cowen compani
model assumptionstermin growth depreci chang work capit valuefre free futur excess number per end septemb cowen
million except per-shar data
compani report cowen compani
cost good gross margin ebitda ebit losses/ incom affili exp tax incom conv sub note deal-rel sever litig incom cont incom deal-rel incom ex-discontinu average ep ex discontinu chang incom cont ep cont end septemb cowen
million except per-shar data
compani report cowen compani
cost good gross margin ebitda ebit losses/ incom affili exp tax incom conv sub note deal-rel sever litig net incom deal-rel incom ex-discontinu average ep ex-discontinu chang year-over-year total incom cont ep cont cowen
million
compani report cowen compani
asset receiv net doubt expens current charg total liabil account payabl incom current equiti common paid-in earn comprehens commmon stock total stockhold liabil stockhold liquid ratio current sale purchas acct ratio inventori structur long-term solvenc ratio total debt total interest ratio return commit capit asset averag stockhold equiti cowen
million
compani report cowen compani
income/ loss flow oper activ depreci provis loss account sale invest employe stock defer incom invest impair oper asset liabil account merchandis prepaid expens account payabl accru expens incom net cash oper acquisit properti acquisit purchas treasuri dividend common proceeds/ repay debt net increase/ decreas cash equival begin cash equival end summari oper year end septemb cowen
million
compani report cowen compani
activitiesnet loss incom discontinu incom continu adjust reconcil net incom provis loss account provis defer incom employe stock loss dispos properti impair charg equiti investment- lifo expense- pension settlement- includ intang asset loss earli retir debt- chang oper asset liabil account merchandis prepaid expens account payabl accru expens incom net cash provid use oper activ continu net cash provid use oper activ discontinu net cash provid use oper invest activitiescapit acquir compani net cash acquired- proce sale properti equiti investments- proce sale purchas invest secur avail sale- other- net cash provid use invest activ continu net cash provid use invest activ discontinu net cash provid use invest financ activitiesborrow revolv securit credit purchas treasuri defer financ cost exercis warrants- exercis stock dividend common purchas cap call other- net cash provid use financ activ continu net cash provid use financ activ discontinu net cash provid use financ increas cash cash cash equival begin cash equival end fiscal year end septemb cowen
use five-year discount cash flow analysi primari valuat method
deriv price target gener assum discount rate may appli
appropri adjust depend compani and/or industri specif factor also
assum termin growth rate depend long-term view specif
sub-industri coverag note discount rate assumpt could view
conserv rel actual weight averag cost capit view
assumpt reason long run lower discount rate assumpt
increas termin growth rate assumpt would lead higher estim valu
per share secondari measur look forward price-to-earnings multipl ev/sal ratio
impli dcf analysi compar histor averag
potenti risk associ drug distribut space industri
highli competit could pressur margin core drug distribut busi
current wave drug patent expir posit impact profit
deriv gener expect taper significantli next sever year
specialti provid signific tailwind industri concern
around sustain high growth biotech sector longer term
impact ppaca expect increas volum could subdu depend
implement execut
number company-specif risk associ pt includ credibl
indic enter pharma suppli chain sharp unexpect declin
gener deflat less expect benefit wbad econodisc
